Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 1/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | STS | P08842 | 10/20 | 0.74 |
| ▸ | CA2 | P00918 | 4/20 | 0.73 |
| ▸ | ESR1 | P03372 | 3/20 | 0.73 |
| ▸ | CA1 | P00915 | 3/20 | 0.73 |
| ▸ | CA9 | Q16790 | 3/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.73 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017878 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5682139 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL12441050 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL959954 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL4570835 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5677806 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL18658723 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL10079402 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL15308964 | 0.91 | HSD17B1 (1.00) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6684274 | 0.90 | HSD17B1 (0.84) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273383-B2 | Administration of 2-methoxyestradiol or it derivatives such as colchicine or combretastatin A-4; for treating and/or preventing a pregnancy related disease; safer and more effective | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-09-25 | — | — | US | claimed |
| EP-2274316-B1 | LIGANDS OF ESTROGEN RECEPTORS AND , METHOD OF THEIR PREPARATION AND PHARMACEUTICALS COMPRISING THEM | USTAV MOLEKULARNI GENETIKY AV CR V V I (CZ) | 2013-02-13 | — | — | EP | disclosed |
| US-8334280-B2 | Ligands of estrogen receptors α and β, method of their preparation, and pharmaceuticals comprising them | Ustav Molekularni Genetikv AV CR, V.V.I. (CZ) | 2012-12-18 | — | — | US | disclosed |
| EP-1067913-B1 | COMPOSITIONS AND METHODS OF ADJUSTING STEROID HORMONE METABOLISM THROUGH FACILITATED ABSORPTION OF HYDROPHOBIC DIETARY COMPOUNDS | BIORESPONSE LLC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20110118225-A1 | Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them | UNIVERZITA KARLOVA V PRAZE, PRIRODOVEDECKA FAKULTA UK (CZ) | 2011-05-19 | — | — | US | disclosed |
| EP-2274316-A1 | LIGANDS OF ESTROGEN RECEPTORS AND , METHOD OF THEIR PREPARATION AND PHARMACEUTICALS COMPRISING THEM | Ustav Molekularni Genetiky Av Cr, V.v.i. (CZ) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009135449-A1 | LIGANDS OF ESTROGEN RECEPTORS α AND β, METHOD OF THEIR PREPARATION AND PHARMACEUTICALS COMPRISING THEM | USTAV MOLEKULARNI GENETIKY AV CR, V.V.I. (CZ) | 2009-11-12 | — | — | WO | disclosed |
| EP-1067913-A4 | COMPOSITIONS AND METHODS OF ADJUSTING STEROID HORMONE METABOLISM THROUGH FACILITATED ABSORPTION OF HYDROPHOBIC DIETARY COMPOUNDS | BIORESPONSE LLC (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008011005-A2 | ANTIANGIOGENIC AGENTS | ENTREMED, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| CN-1315869-C | Osteoporosis resistant estrogen-RGD peptide conjugate and its application in medicine | UNIV CAPITAL MEDICAL SCIENCES (CN) | 2007-05-16 | — | — | CN | disclosed |
| CN-1789278-A | Osteoporosis resistant estrogen-RGD peptide conjugate and its application in medicine | UNIV CAPITAL MEDICAL SCIENCES (CN) | 2006-06-21 | — | — | CN | disclosed |
| WO-2003073985-A2 | NEW METHODS OF USING ANTIANGIOGENIC AGENTS | ENTREMED, INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1067913-A1 | COMPOSITIONS AND METHODS OF ADJUSTING STEROID HORMONE METABOLISM THROUGH FACILITATED ABSORPTION OF HYDROPHOBIC DIETARY COMPOUNDS | Bioresponse, L.L.C. (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6086915-A | HEATING THE SOLUBILIZING EMULSIFIER, ADDING SOLVENT AND ONE OR MORE PHOSPHOLIPID SURFACTANTS, DISSOLVING IN THIS SOLUTION ONE OR MORE HYDROPHOBIC PHYTOCHEMICALS, ADDING ENCAPSULATORS, FORMING MICROEMULSION, SPRAY DRYING THE SOLUTION | BIORESPONSE L.L.C. (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999049851-A1 | COMPOSITIONS AND METHODS OF ADJUSTING STEROID HORMONE METABOLISM THROUGH FACILITATED ABSORPTION OF HYDROPHOBIC DIETARY COMPOUNDS | BIORESPONSE, L.L.C. (US) | 1999-10-07 | — | — | WO | disclosed |
| EP-0409176-A2 | Method and materials for detecting pathology from alterations in estrogen metabolism | THE ROCKEFELLER UNIVERSITY (US) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118225-A1 | Ligands of Estrogen Receptors alpha and beta, Method of Their Preparation, and Pharmaceuticals Comprising Them | ESR2, GPER1, ESRRB | HSD17B1 58/4885LMNA 3966/4885MAPT 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.